These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20544244)

  • 1. When should we use parenteral methotrexate?
    Mainman H; McClaren E; Heycock C; Saravanan V; Hamilton J; Kelly C
    Clin Rheumatol; 2010 Oct; 29(10):1093-8. PubMed ID: 20544244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
    Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
    Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
    Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
    Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral methotrexate for the treatment of rheumatoid arthritis.
    Yazici Y; Bata Y
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study.
    Dhaon P; Das SK; Srivastava R; Agarwal G; Asthana A
    Int J Rheum Dis; 2018 May; 21(5):1010-1017. PubMed ID: 27455886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
    Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
    Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
    Yadlapati S; Efthimiou P
    Rheumatol Int; 2016 May; 36(5):627-33. PubMed ID: 26936262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.
    Schiff M; Jaffe J; Freundlich B; Madsen P
    Expert Rev Med Devices; 2014 Sep; 11(5):447-55. PubMed ID: 24934630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.
    Schiff MH; Sadowski P
    Rheumatol Int; 2017 Feb; 37(2):213-218. PubMed ID: 28012023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate in rheumatoid arthritis.
    Swierkot J; Szechiński J
    Pharmacol Rep; 2006; 58(4):473-92. PubMed ID: 16963793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate.
    Lee WS; Lee SI; Lee MS; Kim SI; Lee SS; Yoo WH
    Korean J Intern Med; 2016 Jul; 31(4):779-87. PubMed ID: 26961485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
    Ruperto N; Murray KJ; Gerloni V; Wulffraat N; de Oliveira SK; Falcini F; Dolezalova P; Alessio M; Burgos-Vargas R; Corona F; Vesely R; Foster H; Davidson J; Zulian F; Asplin L; Baildam E; Consuegra JG; Ozdogan H; Saurenmann R; Joos R; Pistorio A; Woo P; Martini A;
    Arthritis Rheum; 2004 Jul; 50(7):2191-201. PubMed ID: 15248217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate revisited: considerations for subcutaneous administration in RA.
    Jay R
    Clin Rheumatol; 2015 Feb; 34(2):201-5. PubMed ID: 25433918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.